Abstract 166: One-month Modified Rankin Scale (mRS) Score Predicts Five-year Disability, Death, Quality-of-Life, and Healthcare Costs in Ischaemic Stroke

    loading  Checking for direct PDF access through Ovid


Background: Outcome in acute stroke trials is often based on short-term mRS, but there are few data from prospective population-based studies on how this measure translates into long-term outcomes. We evaluated the relationship between 1-month mRS and 5-year disability, death, quality of life, and healthcare cost in a population-based cohort study.

Methods: In 3-month survivors of ischaemic stroke in the Oxford Vascular Study (2002-2014), we used logistic regression to determine predictors of 5-year death/disability, including mRS score at 1 month, age, and sex. The analyses were repeated for different subgroups, including thrombectomy-eligible, atrial fibrillation-related, and lacunar strokes. Hospital resource use and institutionalization data up to 31 August 2015 were collected, and mean censor-adjusted costs were reported with 95% CIs from 1000 bootstrap estimates. A general gamma linear model was used with 1-month mRS controlling for age, sex, and comorbidities. 5-year quality-adjusted life expectancies (QALE) generated from survival data and EQ-5D-derived utility scores were stratified by 1-month mRS.

Results: Among 1,425 survivors, mRS score was a strong independent predictor of 5-year death/disability, with a step-change from mRS 2 to 3: adjusted odds ratio for mRS 3-5 vs 0-2: 35.57, 95%CI 17.40-72.71, p<0.0001. This step-change was also seen for 5-year mortality: adjusted hazard ratio for mRS 3-5 vs 0-2: 1.84, 95%CI 1.59-2.14, p<0.0001. Trends were consistent across the stroke subgroups. mRS score was the only independent predictor of 5-year healthcare costs (p<0.0001) aside from age, again with a step-change from mRS 2 to 3: £8,817.67 (95%CI 6,207.98-10,688.86) vs 29,692.73 (95%CI 21,117.18-31,367.53). 5-year QALE dropped incrementally with rising mRS: mRS=0 - 3.47 (95%CI 3.25-3.66); 1 - 2.91 (2.77-3.04); 2 - 2.64(2.46-2.81); 3 - 1.72 (1.52-1.91); 4 - 1.23 (1.03-1.45); 5 - 0.31 (0.02-0.76).

Conclusions: Our results reaffirm the practice in acute stroke trials of using short-term mRS as the primary outcome measure. The step change between mRS 2 and 3 for both death/disability and healthcare costs supports the traditional dichotomous outcome, but the incremental drop in QALE with each mRS grade shows that ordinal analysis is also valid.

Related Topics

    loading  Loading Related Articles